RT Journal Article
T1 Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection
A1 Álvarez-Mercado, Ana I.
A1 Caballeria-Casals, Albert
A1 Rojano-Alfonso, Carlos
A1 Chávez-Reyes, Jesús
A1 Micó-Carnero, Marc
A1 Sanchez-Gonzalez, Alfredo
A1 Casillas-Ramírez, Araní
A1 Gracia-Sancho, Jordi
A1 Peralta, Carmen
K1 Liver cancer
K1 Liver resection
K1 Growth factors
K1 Regeneration
K1 Hepatocyte growth factor
K1 Insulin-like growth factor-1
K1 Epidermal growth factor
K1 Carcinoma hepatocelular
K1 Hepatectomía
K1 Péptidos y proteínas de señalización intercelular
K1 Regeneración
K1 Factor de crecimiento de hepatocito
K1 Factor I del crecimiento similar a la insulina
K1 Factor de crecimiento epidérmico
AB Hepatocellular carcinoma has become a leading cause of cancer-associated mortality throughout the world, and is of great concern. Currently used chemotherapeutic drugs in the treatment of hepatocellular carcinoma lead to severe side effects, thus underscoring the need for further research to develop novel and safer therapies. Liver resection in cancer patients is routinely performed. After partial resection, liver regeneration is a perfectly calibrated response apparently sensed by the body's required liver function. This process hinges on the effect of several growth factors, among other molecules. However, dysregulation of growth factor signals also leads to growth signaling autonomy and tumor progression, so control of growth factor expression may prevent tumor progression. This review describes the role of some of the main growth factors whose dysregulation promotes liver tumor progression, and are also key in regenerating the remaining liver following resection. We herein summarize and discuss studies focused on partial hepatectomy and liver carcinogenesis, referring to hepatocyte growth factor, insulin-like growth factor, and epidermal growth factor, as well as their suitability as targets in the treatment of hepatocellular carcinoma. Finally, and given that drugs remain one of the mainstay treatment options in liver carcinogenesis, we have reviewed the current pharmacological approaches approved for clinical use or research targeting these factors.
PB MDPI
YR 2021
FD 2021-09-04
LK http://hdl.handle.net/10668/4376
UL http://hdl.handle.net/10668/4376
LA en
NO Álvarez-Mercado AI, Caballeria-Casals A, Rojano-Alfonso C, Chávez-Reyes J, Micó-Carnero M, Sanchez-Gonzalez A, et al. Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection. Biomedicines. 2021 Sep 4;9(9):1158
DS RISalud
RD Apr 7, 2025